Newsletter | September 21, 2022

09.21.22 -- Demystifying Complexity In Pharmaceutical Commercialization

Demystifying The Complexities Of Cell And Gene Therapy Commercialization

Whether coordinating a cell or gene therapy clinical trial or product launch, even the best-planned efforts can be derailed without a clear strategy for facilitating access to the therapy and supporting patients through the treatment journey.

Building A Strategic Framework To Empower Key Account Management

Understand the components of a key account management (KAM) strategic framework that leverages data, dedicated resources, and a clearly defined strategy to set the right foundation for KAM success.

Pharmaceutical Distribution: Right-Sizing The Channel Strategy For Maximum Impact

The goal is to create a nimble, data-driven infrastructure that can connect the therapy to the customer base more effectively, helping to speed therapy onboarding for patients while improving visibility.

Reversing The Complexity Of Oncology Commercialization: How To Solve For Launch Challenges In A Chaotic Ecosystem

Pharma manufacturers must now understand how to navigate influence points within the healthcare ecosystem and support patients through the navigation of access, reimbursement, and affordability barriers.

Avoiding 20% In Investment Waste During Launch

It’s a long-standing perception that pharma overspends during launch, but we can now understand and validate this notion with data. Reasons and cost types were two major sets of drivers for why overspending consistently happened.

Commercialization Strategies In Oncology — The Right Partner Can Reduce Risk And Boost Rewards

Whether you are an emerging company launching your first product or an established company expanding your portfolio, a number of parallel initiatives must be developed and executed to help your therapy get into the limelight.